Nicholas J. Ede

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study”.

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study

Therapeutic Advances in Medical Oncology(2023)10.1177/17588359231210675

N/A

0.296DataRank · unranked

5 citations

Colt A. Egelston, Oscar Colunga Flores, Shyambabu Chaurasiya, David Pei‐Cheng Lin, Helen Chang +17 more

A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)

OncoImmunology(2022)10.1080/2162402x.2022.2127691

N/A

0DataRank · unranked

28 citations

Jay Overholser, Heather Darby, Nicholas J. Ede, Pravin T. P. Kaumaya, Linlin Guo